Author

E. A. Winzeler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 4 Biochemistry· 1 Pharmacology & Toxicology· 1 Physiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 6 Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 3 Organism:mouse· 3 Organism:plant (other)· 3 Approach:genetic perturbation / CRISPR· 2 Organism:human· 2 Assay:proteomics· 2

Frequent Co-Authors

S. Ottilie· 4 shared F. Rocamora· 2 shared G. M. LaMonte· 2 shared M. R. Luth· 2 shared N. Mittal· 2 shared A. B. Vaidya· 1 shared A. Chakraborty· 1 shared A. F. Cowman· 1 shared

Activity by Year

2017-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

S. Ottilie

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

A small-molecule myosin inhibitor as a targeted multi-stage antimalarial

D. V. Trivedi, A. Karabina, G. Bergnes, A. Racca, H. Wander, S. Jung, N. Mittal, T. Huijs, S. Ouchida, P. V. Ruijgrok, D. Song, S. Wittlin, P. Mukherjee, A. Chakraborty, E. A. Winzeler, , J. Spudich

This paper develops a small-molecule myosin inhibitor, KNX-115, effective against multiple stages of Plasmodium infection with high selectivity and potency.

bioRxiv · Sep 9, 2022 · PreprintPharmacology & Toxicology

Development of Highly Selective Epoxyketone-based Plasmodium Proteasome Inhibitors with Negligible Cytotoxicity

J. Almaliti, P. Fajtova, J. Calla, G. M. LaMonte, M. Feng, F. Rocamora, S. Ottilie, E. Glukhov, E. Boura, R. T. Suhandynata, J. D. Momper, M. K. Gilson, E. A. Winzeler, W. H. Gerwick, A. J. O'Donoghue

This study develops highly selective epoxyketone-based proteasome inhibitors effective against Plasmodium falciparum with low cytotoxicity to human cells.

bioRxiv · Aug 6, 2022 · PreprintBiochemistry

Collateral sensitivity as a strategy to suppress resistance emergence: the challenge of diverse evolutionary pathways

R. E. K. Mandt, M. R. Luth, M. A. Tye, R. Mazitschek, S. Ottilie, E. A. Winzeler, M. J. Lafuente-Monasterio, F. J. Gamo, D. F. Wirth, A. K. Lukens

This study investigates collateral sensitivity between DHODH inhibitors to suppress malaria resistance, finding that cross-resistant mutants can emerge despite initial sensitivity.

bioRxiv · Apr 7, 2022Microbiology

Multistage and transmission-blocking targeted antimalarials discovered from the open-source MMV Pandemic Response Box

J. Reader, M. E. van der Watt, D. Taylor, C. Le Manach, N. Mittal, S. Ottilie, A. Theron, P. Moyo, E. Erlank, L. Nardini, N. Venter, S. Lauterbach, B. Bezuidenhout, A. Horatscheck, A. van Heerden, , L.-M. Birkholtz

The paper screens a compound library to identify antimalarial compounds active against multiple Plasmodium life stages and transmission-blocking agents.

bioRxiv · Jun 5, 2020Microbiology

Pan-active imidazolopiperazine antimalarials target the Plasmodium falciparum intracellular secretory pathway

G. M. LaMonte, D. S. Marapana, N. Gnadig, S. Ottilie, M. R. Luth, T. S. Worgall, F. Rocamora, G. M. Goldgof, R. Mohunlal, T. R. S. Kumar, J. K. Thompson, E. Vigil, J. Yang, D. Hutson, T. Johnson, , E. A. Winzeler

This study identifies imidazolopiperazines as targeting the Plasmodium falciparum secretory pathway by inhibiting protein trafficking and ER expansion.

bioRxiv · Aug 15, 2019Microbiology

Plasmodium falciparum Niemann-Pick Type C1-Related Protein is a Druggable Target Required for Parasite Membrane Homeostasis

E. S. Istvan, S. Das, S. Bhatnagar, J. R. Beck, E. Owen, M. LLinas, S. M. Ganesan, J. C. Niles, E. A. Winzeler, A. B. Vaidya, D. E. Goldberg

This study identifies PfNCR1 as a critical protein for Plasmodium falciparum membrane homeostasis and shows it is a potential druggable target for antimalarial drugs.

bioRxiv · Jul 26, 2018Microbiology

Common Piezo1 allele in African populations causes xerocytosis and attenuates Plasmodium infection

S. Ma, S. Cahalan, R. Lohia, G. LaMonte, W. Zeng, S. Murthy, E. Paytas, N. D. Grubaugh, R. Gamini, L. Berry, V. Lukacs, T. Whitwam, M. Loud, A. I. Su, K. G. Andersen, , A. Patapoutian

The paper identifies a common Piezo1 variant in African populations that causes xerocytosis and reduces Plasmodium infection.

bioRxiv · Jul 6, 2017Physiology